Tafen - instructions for use, analogs, reviews and release forms (nasal spray nasal, powder for inhalation Novolayzer, drops in the nose) drugs for the treatment of polyps, rhinitis or rhinitis in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Tafen. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Tafen in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Tafen with available structural analogues. Use for the treatment of polyps, rhinitis or rhinitis,including allergic in adults, children, as well as during pregnancy and lactation. Composition of the hormonal drug.

Tafen - Glucocorticosteroid (GCS) for intranasal (in the nose) application. Has a pronounced anti-inflammatory and antiallergic effect. When used in therapeutic doses, it practically does not exert a resorptive effect. It does not have mineralocorticoid activity, it is well tolerated with long-term treatment. The drug has an inhibitory effect on the release of mediators of the inflammatory reaction, increases the synthesis of anti-inflammatory proteins, reduces the number of mast cells and eosinophilic granulocytes.

Budesonide (active ingredient of the drug Tafen) reduces the release of toxic proteins from eosinophils, free radicals from macrophages and lymphokines from lymphocytes. It also reduces the binding of adhesive molecules to endothelial cells, thus reducing the flow of leukocytes to the site of allergic inflammation.

Budesonide increases the number of beta-adrenoreceptors of smooth muscle. The drug inhibits the activity of phospholipase 2A, which leads to inhibition of the synthesis of prostaglandins, leukotrienes and PAF,inducing an inflammatory response. Budesonide also inhibits the synthesis of histamine, which leads to a decrease in its level in the mast cells.

Tafen nasal reduces the severity of symptoms in allergic rhinitis, suppresses the late and early phases of an allergic reaction and reduces inflammation in the upper respiratory tract. Improvement of the condition is observed on the 2-3 day after the start of treatment.

It is a hormonal drug.

Composition

Budesonide + auxiliary substances.

Pharmacokinetics

Only about 20% of the intranasally administered dose of Tafen falls into the systemic circulation. Systemic bioavailability of budesonide is low; More than 90% of the absorbed drug is inactivated during the single-stage metabolism in the liver. Glucocorticoid activity of metabolites does not exceed 1%. Metabolites are excreted mainly with urine (70%) and with feces.

Indications

• prevention and treatment of seasonal and all-year-round allergic rhinitis;
• non-allergic rhinitis;
• polyps of the nose.

Forms of release

Spray nasal dosed with 50 mcg (Nazal).

Powder for inhalation dosed (Novolayzer).

Other dosage forms, whether drops in the nose, pills or capsules, do not exist.

Instructions for use and dosage

Spray Tafen Nazal

Adults and children over the age of 6 years at the beginning of therapy are prescribed 2 doses (50 μg Budesonide) per nostril 2 times a day. The usual maintenance dose is 1 dose in each nostril 2 times a day or 2 doses in each nostril once a day, in the morning. The maintenance dose should be the lowest effective dose that relieves the symptoms of rhinitis.

The maximum single dose is 200 μg (100 μg per each nostril), the maximum daily dose is 400 μg for no more than 3 months.

A full therapeutic effect requires regular and correct application.

If the dose is missed, it should be taken as soon as possible, but not less than 1 hour before the next regular dose.

Side effect

• irritation of the mucous membrane of the nose and throat;
• nose bleed;
• cough;
• dryness of the nasal mucosa;
• sneeze;
• dermatitis;
• hives;
• rash;
• fatigue;
• dizziness;
• perforation of the nasal septum;
• angioedema;
• loss of smell;
• tachycardia;
• growth retardation.

With the use of the drug, side effects develop very rarely and are of a transient nature.

Contraindications

• Fungal, bacterial and viral infections of the respiratory tract;
• active form of pulmonary tuberculosis;
• children under 6 years;
• hypersensitivity to budesonide or any other component of the drug.

Application in pregnancy and lactation

The use of the drug Tafen during pregnancy is allowed only if the expected benefit for the mother exceeds the possible risk to the fetus.

If it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued.

Use in children

The drug is prescribed for children older than 6 years.

special instructions

When switching from treatment with systemic GCS to nasal spray treatment, due to the risk of developing adrenal insufficiency, caution is required for the recovery period of the function of the hypothalamic-pituitary-adrenal system.

Because SCS slows wound healing, caution should be exercised in appointing Tafen to patients who have recently suffered an injury or nose operation.

For a full therapeutic effect in allergic rhinitis, it is required to take the drug on a regular basis.

It is recommended to avoid contact with eyes.

Impact on the ability to drive vehicles and manage mechanisms

Tafen does not affect the ability to drive a car or machinery.

Drug Interactions

The simultaneous use of the drug Tafen Nazal with inducers of microsomal oxidation (phenobarbital, phenytoin, rifampicin) may reduce the effectiveness of the former.

Methandrostenolone, estrogens, Ketoconazole increase the action of budesonide.

Analogues of the drug Tafen

Structural analogs for the active substance:

• Apulein;
• Benacap;
• Benacorte;
• Benarin;
• Budenit;
• Budenofalk;
• Budesonide;
• Budiere;
• Budostere;
• Novopulmon E Novolayzer;
• Pulmicort;
• Pulmicort Turbuhaler;
• Tafen Nazal;
• Tafen Novolayzer.

Similar medicines:

Other medicines: